Athenagen, a biotech start-up in South San Francisco focused in the area of neurovascular diseases, said it has raised $50 million through a Series B financing.

The funds will be used primarily to advance development of the company’s lead programs targeting Alzheimer’s disease, age-related macular degeneration (AMD) and cognition enhancement, the company said.

The financing was co-led by Sanderling Ventures and Clarus Ventures, with a significant investment also made by Index Ventures. Current investors, Charter Life Sciences and Astellas Venture Management, also participated in the round. As a result of the financing, Dennis Henner, Ph.D., a Managing Director of Clarus Ventures, will take a seat on Athenagen’s board of directors, the company said.

VentureBeat

VentureBeat's mission is to be a digital town square for technical decision-makers to gain knowledge about transformative technology and transact. Our site delivers essential information on data technologies and strategies to guide you as you lead your organizations. We invite you to become a member of our community, to access:
  • up-to-date information on the subjects of interest to you
  • our newsletters
  • gated thought-leader content and discounted access to our prized events, such as Transform
  • networking features, and more
Become a member